Chronic Heart Failure - Epidemiology Forecast - 2034

Chronic Heart Failure - Epidemiology Forecast - 2034

Key Highlights

In 2023, there were around nearly 20,364,270 diagnosed prevalent cases of CHF in the 7MM, which is expected to rise by 2034, and the US had the highest number of diagnosed prevalent cases of CHF among the 7MM.

Germany had the highest number of diagnosed prevalent cases of CHF in the EU4 countries, followed by Italy, whereas France had the lowest number of cases.

When it comes to age-specific cases of CHF, the age group between more than 60 years had the highest number of cases, accounting for nearly 903,650 cases in the UK, followed by 40-59 years, and the least number of cases were observed with people less than 39 years.

DelveInsight’s “Chronic Heart Failure (CHF) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CHF, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Chronic Heart Failure (CHF) Understanding

CHF Overview

CHF commonly referred to as heart failure is a chronic progressive condition in which the heart cannot generate a cardiac output sufficient to meet the body’s demands without increasing diastolic pressure resulting from any cardiac disease compromising ventricular systolic or diastolic function. The common term for describing heart failure is based on left ventricular ejection fraction. Also, heart failure with normal LVEF (≥50%) is known as heart failure with preserved ejection fraction and heart failure with decreased LVEF (<40%) as heart failure with reduced ejection fraction. Heart failure with a 40–49% middle range is known as Heart Failure with mid-range Ejection Fraction (HFmrEF). The signs and symptoms of CHF are subtle at the initial stage, and these are generally misguided for common signs of aging. The common symptoms of CHF are because of extra fluid or congestion, which leads to vessel blocking. The starting of the congestion in the lungs is forwarded to the different body parts.

CHF Diagnosis

The assessment for CHF is achieved using numerous parameters, like physical testing of the patient to know the occurrence of clinical symptoms of heart failure, various blood tests, urine analysis, fasting glucose, and lipid profile, metabolic profiling for serum electrolytes, and thyroid hormone estimation. Apart from these routine tests, different imaging techniques like chest X-ray, ECG, MRI, and others are used for diagnosing CHF.

The patient’s journey begins with the onset of symptoms like breathlessness at night, congestion of the lungs, difficulty in walking, and edema in the legs. Following an initial visit with a general practitioner, during which the patient underwent a complete physical examination, and the results revealed a few alarming findings related to CHF, the patient was referred to a cardiologist. Further, the cardiologist will immediately recommend a blood examination, assessment of brain natriuretic peptide (BNP) or N-terminal pro-b-type BNP (NT-proBNP), and ECG is prescribed to diagnose heart failure. If the test result shows an increased BNP level and an abnormal ECG—the possibility of heart failure is confirmed. Once heart failure is confirmed an echocardiogram is done to measure the ejection fraction, which helps in identifying causes and stages of heart failure, and also helps in undertaking proper treatment decisions.

Further details related to diagnosis will be provided in the report…

Chronic Heart Failure (CHF) Epidemiology

The CHF epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of heart failure, gender-specific cases of heart failure, ejection fraction-specific cases of heart failure, NYHA class-specific cases of heart failure, type-specific cases of heart Failure, and age-specific cases of heart failure in the 7MM covering the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2020 to 2034.

As per DelveInsight estimates, the total diagnosed prevalent cases of heart failure in the 7MM comprised nearly 20,364,270 cases in 2023 and are projected to increase during the study period of 2020-2034.

The US had the highest number of diagnosed prevalent cases of heart failure in 2023, with approximately 7,075,620 reported cases.

In 2023, there were nearly 4,346,790 patients affected with Heart Failure with preserved Ejection Fraction (HFpEF), 2,011,840 patients with Heart Failure with reduced Ejection Fraction (HFrEF), and 7,161,000 with Heart Failure with medium Ejection Fraction (HFmEF) in the US.

In 2023, the highest number of heart failure cases were in the age group of ≥60 comprising nearly 4,444,230 cases followed by the age group of 40–59 comprising nearly 634,900, while the least number of cases were in the age group of less than 39 comprising nearly 211,630 in Japan.

CHF Report Insights

CHF Report Insights

Patient Population

Country-wise Epidemiology Distribution

CHF Report Key Strengths

Eleven Years Forecast

7MM Coverage

AKI Epidemiology Segmentation

FAQs

What are the disease risks, burdens, and unmet needs of CHF? What will be the growth opportunities across the 7MM concerning the patient population with CHF?

What is the historical and forecasted CHF patient pool in the US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.